The association between elevated serum uric acid (SUA) levels and risk of cardiovascular (CV) disease has gained a lot of attention over the last years, considering that using the cut-off levels derived from gout data (6 mg/dl in women and 7 mg/dl in men), the prevalence of hyperuricemia in general population ranges from 20 to 25% [1–3]. Many epidemiological studies reported that elevated SUA levels are a powerful predictor of adverse clinical outcomes in patients with hypertension, diabetes, ischemic heart disease, stroke, chronic kidney disease or heart failure (HF) [4–7].
